In this study,we designed and engineered a two-component recombinant fusionprotein antigen as a vaccine candidate against the possible biological threat of Yersinia pestis.Therecombinant F1-V protein was formulated wi...In this study,we designed and engineered a two-component recombinant fusionprotein antigen as a vaccine candidate against the possible biological threat of Yersinia pestis.Therecombinant F1-V protein was formulated with Alhydrogel.A four-time injection with a dosage of10,20 and 50 ug/mouse in about two months was adopted for vaccination.Serum antibodies and subclassof T helper cells were measured and analyzed.After the final vaccination,the mice were challenged by141 strain with 25- 600 LD50.In conclusion,the recombinant vaccine was capable of inducingprotective immunity against subcutaneous challenge.The level of serum IgG was supposed to be a mainfactor that affected the final protection of challenge.20 ug recombinant protein could induce anendpoint titre of serum IgG as high as 51200,which was enough to afford 100% protection against 400LD50 virulent 141 challenge.The antibody isotype analysis showed that the vaccine inducedpredominantly an lgG1 rather than lgG2a response.Flow cytometric analysis revealed that Alhydrogelsignificantly helped induce a stronger humoral immunity instead of CTL cellular response.Thesefindings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine.展开更多
文摘In this study,we designed and engineered a two-component recombinant fusionprotein antigen as a vaccine candidate against the possible biological threat of Yersinia pestis.Therecombinant F1-V protein was formulated with Alhydrogel.A four-time injection with a dosage of10,20 and 50 ug/mouse in about two months was adopted for vaccination.Serum antibodies and subclassof T helper cells were measured and analyzed.After the final vaccination,the mice were challenged by141 strain with 25- 600 LD50.In conclusion,the recombinant vaccine was capable of inducingprotective immunity against subcutaneous challenge.The level of serum IgG was supposed to be a mainfactor that affected the final protection of challenge.20 ug recombinant protein could induce anendpoint titre of serum IgG as high as 51200,which was enough to afford 100% protection against 400LD50 virulent 141 challenge.The antibody isotype analysis showed that the vaccine inducedpredominantly an lgG1 rather than lgG2a response.Flow cytometric analysis revealed that Alhydrogelsignificantly helped induce a stronger humoral immunity instead of CTL cellular response.Thesefindings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine.
